| Business Summary | | Genta,
Inc.
is
a
biopharmaceutical
company
whose
research
efforts
are
focused
on
the
development
of
new
biopharmaceutical
products
for
the
treatment
of
patients
with
cancer.
The
Company's
research
portfolio
is
currently
divided
into
four
areas
including
the
Antisense
Program,
which
involves
the
administration
of
synthetic
oligonucleotides
that
are
complementary
to
specific
mRNA
transcripts;
the
Gallium
Products
Franchise,
which
is
a
bone-seeking
element
that
exerts
potent
effects
on
the
skeletal
system;
Androgenics
Compounds,
which
are
products
comprised
of
a
portfolio
of
small
molecules
that
are
useful
for
the
treatment
of
prostate
cancer;
and
Decoy
Aptamers,
which
employ
oligonucleotides
to
bind
to
specific
proteins
known
as
transcription
factors. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GNTA
is
a
biopharmaceutical
company
that
focuses
its
research
on
the
development
of
new
products
for
the
treatment
of
patients
with
cancer.
For
the
six
months
ended
6/30/01,
revenues
totaled
$82
thousand,
up
from
$0.
Net
loss
applicable
to
Common
increased
21%
to
$18.4
million.
Revenues
reflect
the
inclusion
of
licence
revenues.
Net
loss
reflects
an
increase
in
payroll
and
marketing
expenses
and
the
inclusion
of
a
$1
million
Promega
settlement
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Raymond Warrell, Jr., M.D., 50 Chairman,
Pres, CEO | $142K | Michael Weiss, 34 Vice
Chairman | -- | Alfred Fernandez CFO,
Exec. VP | -- | Loretta Itri Exec. VP, Clinical R&D, CMO | -- | Bruce Williams Sr.
VP of Sales and Marketing | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|